Harrow Q2 2026 revenue up 60% sequentially to $70.7M
Harrow reported a 60% sequential revenue increase to $70.7 million for Q2 2026, exceeding revenue guidance and highlighting strong demand across its ophthalmological product portfolio.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day